Links

ACR 2015



An easy guide to ACR 2015 - Systemic Lupus Erythematosus: join the tour!


PANLAR, and its Lupus Study Group: GLADEL (Grupo Latino Americano De Estudio del Lupus) invite you to visit this guide and find a day-by-day list of the most important studies and sessions of the ACR upcoming meeting in San Francisco, that will focus on this disease.

We also would like to invite you to attend the “Latin American Study Group meeting” that will take place on Sunday, November 8, from 1:00 to 2:00 PM, West room, Nº 2018.

We hope this guide will meet your expectations. Enjoy the meeting.




Sunday, November 8, 2015

Session Type: ACR Sessions
Session Time: 7:30 – 8:30 AM

The Interferonopathies – West – 2022
Year in Review – South – Hall A



Session Type: ACR Poster
Session A and Poster Tours Session Time: 09:00 – 11:00 AM

Session Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

# 13. Altered Soluble Mediators, Autoantibodies, and Lupus-Specific Connective Tissue Disease Questionnaire Scores Distinguish Blood Relatives with Incomplete Lupus from Unaffected Relatives and Relatives with Classified SLE

Session Title: Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

# 24. Investigating the Role of Vitamin D in the Transition to Systemic Lupus Erythematosus in Individuals at Risk for the Disease

# 37. Cardiovascular Disease in Immune-Mediated Inflammatory Diseases: Cross Sectional Analysis of the Influence of Demographic and Traditional Cardiovascular Risk Factors

# 51. Oral Glucocorticoid Use Is Associated with Osteonecrosis in Adults with Chronic Inflammatory Diseases but Not in Children: A Population-Based Cohort Study

# 54. Impact of Age at Disease Diagnosis on Clinical Manifestations, Disease Activity, and Outcomes in Patients with Systemic Lupus Erythematosus: Single-Center Prospective Cohort Study

# 55. Increased Incidence of Tuberculosis Among Systemic Lupus Erythematous Patients – Should Tuberculosis Screening at Diagnosis be the Next Step?

# 56. Utilizing City-Wide Electronic Health Record Data to Assess Care Fragmentation in Patients with Systemic Lupus Erythematosus (SLE)

# 57. Age, Gender, Racial and Comorbidity Differences Among Systemic Lupus Erythematosus Patients Hospitalized with Ischemic Stroke Compared to the General Population: A Nationwide Analysis

# 58. Attribution of Cause of End-Stage Renal Disease Among Systemic Lupus Erythematosus Patients

# 59. Variation in Heart Failure Hospitalizations Among U.S. Medicaid Recipients with SLE 2000-2010, By Race and Ethnicity

# 60. Mortality of Systemic Lupus Erythematosus in Puerto Rico Assessed By Multiple-Cause-of-Death Analysis

Session Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

# 73. Anti -N-Methyl-D-Aspartate Receptor Antibody Is Associated with Fibromyalgia in Patients with Systemic Lupus Erythematosus

Session Title: Genetics, Genomics and Proteomics

# 88. Integrating Evidence for Genetic Association and Natural Selection Helps Detect New Systemic Lupus Erythematosus Risk Loci in African-Americans

# 90. Influence of Susceptible HLA-DRB1 Alleles on Clinical Subphenotypes of Systemic Lupus Erythematosus in Koreans

# 94. NGS Panel for the Detection of Monogenic SLE in Children: Initial Results

# 108. A New Susceptibility Locus for Systemic Lupus Erythematosus on Chromosome 12

Session Title: Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

# 120. Validity of the Inpatient Diagnosis of Systemic Lupus Erythematosus: Clarifying Hospital Readmission Rates

# 136. Physician Patterns of Patient Care in Systemic Lupus Erythematosus: Are We Ordering Unnecessary Tests?

# 149. Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus (SLE) Initiating Treatment with Belimumab in a US Commercially Insured Database: 2010-2014

Session Title: Innate Immunity and Rheumatic Disease

# 198. CL-L1 and CL-K1 Complement Associated Pattern Recognition Molecules in Systemic Lupus Erythematosus

# 210. Phenotypically Divergences of Monocyte Subsets and Microparticles in Systemic Lupus Erythematosus Patients

Session Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Lupus, Scleroderma, JDMS

# 385. Urinary Cell-Free Microrna’s As Biomarkers of Lupus Nephritis in Children

# 386. Chronic Arthritis in Systemic Lupus Erythematosus: Distinct Features in 336 Pediatric and 1,830 Adult Patients

# 387. Features of 847 Childhood-Onset Systemic Lupus Erythematousus Patients in Three Age-Related Groups at Diagnosis: A Brazilian Multicenter Study

# 388. Pain, Fatigue and the Psychological Impact on Health-Related Quality of Life in Childhood-Onset Lupus

# 389. Clinical and Serological Differences Between Juvenile-Onset and Adult-Onset Systemic LUPUS Erythematosus Patients from a National Registry of Patients

# 390. Treatment and Outcomes in Pediatric SLE Patients in South Africa

# 391. Current Provider Practices and Perceived Barriers for Mental Health Care of Adolescents with SLE

# 392. From Childhood to Adulthood: Longitudinal Trajectory of Damage in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)

# 393. From Childhood to Adulthood: Identifying Latent Classes of Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus Patients

# 394. Clinical Features of Children with Silent Lupus Nephritis

# 395. Depression Risk Among Adults with Childhood- and Adult-Onset Systemic Lupus Erythematosus: 11 Years of Follow-up

# 396. A Comparison of the Illness Experience Reported Via the Patient Reported Outcomes Measurement Information System Between Patients with Childhood-Onset Systemic Lupus Erythematosus, Juvenile Idiopathic Arthritis, and Widespread Chronic Musculoskeletal Pain

# 397. Longitudinal Observation of Psychological Factors and Health-Related Quality of Life in Childhood-Onset Lupus

# 399. Management of Lupus Anticoagulant Hypoprothrombinemia Syndrome in Juvenile Systemic Lupus Erythematosus: Single Center Experience

# 400. Disease Activity and Health Care Utilization Among Young Adults with Childhood-Onset Lupus Transitioning to Adult Care: Data from the Pediatric Lupus Outcomes Study

# 401. Racial and Ethnic Disparities in Depression Diagnosis and Treatment for Adolescents with SLE: Analysis of a National Medicaid Sample

# 402. Predicting Area Under the Curve of Mycophenolate Mofetil in Childhood-Onset Systemic Lupus Erythematosus

# 403. Proteinuria in Childhood Onset Lupus Nephritis: When Does It Go Away ?

# 404. Long-Term Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus

# 405. Anti-C1q Antibodies As Potential Diagnostic and Prognostic Biomarkers in Juvenile Systemic Lupus Erythematosus

# 406. Long Term Follow up of Inner City Pediatric Patients with Lupus Nephritis

# 407. Inter-Observer Variability of the Histological Classification of Lupus Glomerulonephritis in Children

# 408. Characterization of Pediatric Systemic Lupus Erythematosus with Acquired Angioedema

# 422. Mood Disorder Is Highly Prevalent in a Multi-Ethnic Urban Pediatric Lupus Cohort

# 423. Institutional and Regional Variation in Childhood SLE 30-Day Hospital Readmission Rates: A Comparative Effectiveness Research Using the Pediatric Health Information System Database

# 425. Impact of in Utero Hydroxychloroquine Exposure on Age of Onset of Cutaneous Neonatal Lupus

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

# 715. Investigating the Role of Vitamin D in Patients with SLE

# 716. Urinary Proteomics Identifies Three Novel Biomarkers for Lupus Nephritis Activity: Retinol Binding Protein, Alpha-1-Antichymotrysin and Haptoglobin

# 717. Systemic Lupus Erythematosus and the Evaluation of Poor Sleep: The Sleeps Pilot Study

# 718. Urinary MBL : A Promising Biomarker for Predicting Flare in Lupus Nephritis

# 719. Cell of Origin of Diffuse Large B-Cell Lymphoma (DLBCL) in Patients with Systemic Lupus Erythematosus (SLE)

# 720. Biomarkers in Lupus Nephritis: The Possible Role of Serum Cystatin C, Serum β2-Microglobulin, Urinary α1-Microglobulin and Albumin/Creatinine Ratio

# 721. Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Systemic Lupus Erythematosus

# 722. Biomarkers/Pathways Discovery of Lupus Nephritis By Urine Proteomics

# 723. Oral Ulcers in Systemic Lupus Erythematosus: Characterization and Clarification of an Important Clinical Manifestation

# 724. Mycophenolate Mofetil in Non-Renal Manifestations of Systemic Lupus Erythematosus. an Observational Cohort Study

# 726. Associates of Pleurisy of Pericarditis in Systemic Lupus Erythematosus (SLE)

# 727. Repository Corticotropin Injection (H.P. Acthar® Gel) Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids

# 728. Autoimmune Hemolytic Anemia and Thrombocytopenia in a Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey : Clinical Associations and Effect on Disease Damage and Survival

# 729. The Effect of Belimumab on Peripheral Blood Cells in Patients with Systemic Lupus Erythematosus

# 730. Early Symptoms of Systemic Lupus Erythematosus As Reported By Members of the German Lupus Erythematosus Patient Association

# 731. Damage and Mortality in SLE: Cluster Analysis of Patients from SLE Registry from the Spanish Society for Rheumatology (RELESSER)

# 732. Decreased Disease Activity and Corticosteroid Usage and Improved Quality of Life during Belimumab Treatment in Patients with Systemic Lupus Erythematosus: a Prospective Real-Life Observational Study

# 733 Late Onset Systemic Lupus Erythematosus: A Different Disease Subset?

# 734. Disease Patterns, Flare Incidence and Organ Damage Among Filipino Patients with Systemic Lupus Erythematosus: a One-Year Observational Study

# 735. Belimumab Reduces the Frequency of Flares and Prevents Damage Progression in SLE Patients: Experience in a Clinical Practice Setting

# 736. Complement Activation As a Marker for Increased Thrombosis Risk in SLE Patients with Antiphospholipid Antibodies

# 737. A Paper Patient-Based Flare Study in SLE

# 738. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BCL-2 Inhibitor Venetoclax (ABT-199) in a Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus

# 739. Prednisone Increases Both Arterial and Venous Thrombosis in SLE

# 740. The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus

# 741. Satisfaction and Impact Associated with the Addition of Belimumab to Systemic Lupus Erythematosus (SLE) Treatment: A Cross-Sectional Survey of US Rheumatologists and Their Patients

# 742. IgM Antibodies Against Malondialdehyde and Phosphorylcholine Are T Cell Dependent and Strong Protection Markers for Atherosclerosis in SLE

# 743. Behavior of Complement Levels and Risk of Organ Involvement in SLE Patients

# 744. Longitudinal Assessment of Th1 and Th2 Cytokines: A Comparison Between Adult-Onset and Childhood-Onset Systemic Lupus Erythematous

# 745. Changes in Serum Albumin Levels Correlate Highly with Severity and Activity of SLE

# 746. Multi-Center Delphi Exercise Reveals Important Key Items in Classifying SLE

# 747. Depletion of Serum Soluble CD40L Characterizes the Association Between Systemic Lupus Erythematosus and Thrombotic Thrombocytopenic Purpura: Longitudinal, Single-Center Study

# 748. Comparison of Systemic Lupus Erythematosus in 3 Different Asian Ethnic Groups: Results from the 1000 Faces of Lupus Cohort

# 749. Microvesicles Containing Nucleic Acids and Expressing Immunoglobulins and HMGB1 Are Abundant in Patients with Systemic Lupus Erythematosus

# 750. Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and Meta-Analysis

# 751. Rituximab Induced Serum Sickness: A Systematic Review

# 752. A Strong Association Between Gout and Diuretic Use Among Lupus Patients

# 753. Serum Levels of Tenascin-C Discriminate Patients with Active SLE from Inactive Patients and Healthy Controls, and Predict the Need to Escalate Immunosuppressive Therapy

# 754. Glutathione S Transferases (GST) Polymorphisms Are Independents Predictors of Efficacy and Toxicity in Lupus Nephritis Treated with Cyclophosphamide

# 755. Validating the RAIL Algorithm in Adult Lupus Nephritis Patients

# 756. Axl, Ferritin, IGFBP2 and TNFR2 As Biomarkers in Systemic Lupus Erythematosus

# 757. The Ratio Between TNF-a and P-Albumin, – a Suggested Measure of Disease Activity in SLE

# 758. Dominican Patients with Systemic Lupus Erythematosus Residing in New York City Have a Higher SLICC/ACR Damage Index Than Those in the Dominican Republic

# 759. Prolactin Level Is Independently Associated with Circulating CD4+CD28null in Systemic Lupus Erythematosus Patients

# 760. Impact of Baseline Concomitant Medication Use on Belimumab Efficacy and Safety in Patients with Systemic Lupus Erythematosus (SLE)

# 761. Neurometabolic Alterations in Korean Lupus Patients with Chronic Daily Headache

# 762. The Interferon Signature Correlates with Longitudinal Disease Severity in Systemic Lupus Erythematosus, but Adds Little to Conventional Prognostic Indicators

# 763. Lupus-Related SNPs and Risk of Diffuse Large B-Cell Non-Hodgkin Lymphoma

# 764. Gastrointestinal Adverse Events of Azathioprine in Daily Clinical Practice: Independent of Thiopurine Methyltransferase Activity

# 765. Clinical Improvements in Systemic Lupus Erthematosus Are Correlated to Cellular and Soluble Biomarkers in Classical Complement Pathway

# 766. Clinical and Immunological Characteristics of 150 Systemic Lupus Erythematosus Patients in Urban Jamaica

# 767. Estimating the Pre-Test Probability of Systemic Lupus Erythematosus By Utilizing Anti-Double Stranded DNA and Cell Bound Complement Activation Products Testing from Rheumatology Based Practices in the United States

# 768. The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Instrument Correlates Between Trained Clinical Investigators and Clinicians

# 769. Evaluation of Soluble Alpha-Klotho in Neuropsychiatric Systemic Lupus Erythematosus

# 770. Circulating Levels of iC3b and C3 Correlate with Sledai-2K Responder Index-50 (S2K RI-50) Disease Activity Scores: The Castle (Complement Activation Signatures in Systemic Lupus Erythematosus) Study

# 771. Convergent Validity of New Disease Assessment Instruments in Systemic Lupus Erythematosus in Relation to Sledai-2K

# 772. Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays

# 773. Clinical Evaluation of Patients with Positive Antibodies to Extractable Nuclear Antigens but Negative ANA

# 774. Anti-Nuclear Antibodies Have High Sensitivity for Systemic Lupus Erythematosus: Results of a Systematic Literature Review and Meta-Regression of Diagnostic Data

# 775. Identification of Candidate Items for Revised Classification Criteria for Systemic Lupus Erythematosus

# 776. Sensitivity of Antinuclear Antibody By Immunofluorescence Testing for Detection of Anti-Ro/SSA Antibodies

# 777. SLE-KeyTM Rule-out Test to Assess Lupus in Anti-Nuclear Antibody Positive Subjects Using the Immunarray iCHIP®

# 778. Associations Between Autoantibodies and Clinical Manifestations in Systemic Lupus Erythematosus: Data from a Multiethnic Latin American Cohort

# 779. Mapping Perceptions of Medication Decision Making Facilitators: The Importance of Patient Context

# 780. Long-Term Prognosis and Factors Associated with Damage Accrual in Japanese Patients with Systemic Lupus Erythematosus

# 781. Anti-Nucleosome Antibodies Versus Anti-DNA Antibodies in the Diagnosis and Monitoring of Activity of Systemic Lupus Erytematosus

# 782. A Proposal for Assessing Systemic Lupus Erythematosus Activity By a Multimodal Instrument That Includes Clinical Variables, Physician Assessment and Modification of Treatment

# 783. Osteonecrosis in Systemic Lupus Erythematosus: Predictive Factors

# 784. Electronic Health Record (EHR) As a Powerful Tool to Establish Clinical Research Lupus Cohorts

# 785. Further Validation of Simple Index As a Simple Disease Activity Assessment Tool for SLE

# 786. Anti-Carbamylated Protein Antibodies Identify Systemic Lupus Erythematosus Patients with Erosive Arthritis: Analysis of a Regional Swedish Register

# 787. Validation of Lupuspro V1.8, Disease Targeted Patient Reported Outcome for Systemic Lupus Erythematosus

# 788. Identification of Molecular Biomarkers to Distinguish Systemic Lupus Erythematosus with Skin Involvement from Discoid Lupus Erythematosus and Subacute Cutaneous Erythematosus: Provisional Results from Cross-Sectional Studies

# 789. Direct Coombs Positivity in SLE

# 790. An Intervention to Improve Quality of Life for African-American Lupus Patients

# 791. Impact of Online Education and Social Media Intervetion for Self-Management in Adolescents with SLE

# 792. Incidence and Persistence of Cervical Human Papillomavirus Infection in Mexican Systemic Lupus Erythematosus Women

Session Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis

# 793. Mesenchymal Stem Cells Promote the Generation of CD206+ Macrophage and Increase Its Phagocytic Activity in Systemic Lupus Erythematosus

# 794. CD163+ Macrophages Display Mixed Polarizations in Discoid Lupus Skin

# 795. High Mobility Group Box-1 (HMGB1) Affects Macrophage Polarization and Phagocytosis in Systemic Lupus Erythematosus Patients

# 796. Single Cell Gene Expression Studies in Lupus Patient Monocytes Reveal a Unique Anti-Inflammatory Population of Non-Classical Monocytes Associated with Clinical Quiescence

# 797. Divergent Phenotypic Patterns Between Systemic Lupus Erythematosus and Healthy Anti-Nuclear Antibody Positive Individuals Reveal Distinct Differences in B Cell and Myeloid Populations Among Ethnicities

# 798. Keratinocyte-Associated IL-6 Is Elevated in Cutaneous Lupus Rashes and Production of IL-6 By Keratinocytes Is Enhanced in Non-Involved Lupus Skin

# 799. Transcriptional Profiling of Cutaneous Lupus Reveals Pronounced Changes in Keratinocyte and Myeloid Lineage Expressed Genes and Demonstrates Uniquely Regulated Interferon Pathways Between Rash Subtypes

# 800. A High-Throughput System for Quantification of in Vitro Neutrophil Extracellular Trap Formation with Fluorescence Immunocytochemistry

# 801. Artesunate Modulates Atherosclerosis Related Factors through the Inhibition of STAT1

# 802. Identification of Cyclin-Dependent Kinase 1 As a Novel Regulator for Controlling Type I Interferon Signaling in Systemic Lupus Erythematosus

# 803. Interferon-Alpha Mediated Lowering of Pentraxin-3 Levels in Systemic Lupus Erythematosus?

# 804. Prolactin Induces Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation in Primary Monocytes Comparable to Changes Seen in Monocytes from Systemic Lupus Erythematosus Patients

# 805. Interferon Activity in Early and Established SLE: Interferon Score Is Lower in Early Disease and Not Seen without Antibodies to Extractable Nuclear Antigens

# 806. STAT1 Activation Promotes TLR8 Overexpression and Facilitates Mirokine Signaling Via Exosomes Containing a Mir-21 Endogenous Ligand: A Novel Innate Inflammatory Pathway in Systemic Lupus Erythematosus

# 807. High Levels of Serum IFN-Alpha Mark a Subgroup of SLE Patients with Distinct Immunophenotypic Features and Hyperresponsiveness to Toll-like Receptor Stimulation

# 808. Heritable Endotheliopathy and ApolipoproteinL1 Risk Traits in SLE

# 809. Patients with SLE Who Are Anti-Factor Xa IgG Positive Are Less Likely to Have Atherosclerotic Plaque

# 810. Human Parvovirus B19 Nonstructural Protein 1 (NS1) Helicase Breaks Tolerance to Self dsDNA: A Model for Viral Induction of Autoimmunity

# 811. Antibody Response to Periodontogenic Bacterium Aggregatibacter Actinomycetemcomitans and Lupus

# 812. SLAMF3 Mediated Co-Stimulation Promotes Activation of the IL-2/IL-2R/STAT5 Pathway and Regulatory T Cells Differentiation in Human Naïve CD4+ T Cells – Implications for SLE

# 813. Expression of Inducible Costimulator Ligand (ICOSL) on CD4+ T Cells in Patients with Systemic Lupus Erythematosus

# 814. Lupus Drives Atherosclerosis through CD4+CXCR3+ T Cells and Plasmacytoid Dendritic Cells

# 815. Lys63-Polyubiquitination By the E3 Ligase Casitas B-Lineage Lymphoma-b Modulates Peripheral Regulatory T Cell Tolerance in Patients with Systemic Lupus Erythematosus

# 816. Incomplete Tolerance in Anergic B Cells in SLE: T Helper Signals Restore B Cell Receptor Signaling in Autoreactive Anergic B Cells By Upregulating CD45 Phosphatase Activity

# 817. Circulating Endothelial Cell (CEC) and CEC-Bound C4d Levels As Biomarkers of Systemic Lupus Erythematosus

# 818. Cell-Bound Complement Activation Products (CB-CAP) Profiles in Patients with Pre-Systemic Lupus Erythematosus

# 819. Upregulation of Complement C3 and Alpha-2-Macroglobulin in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus

# 820. Peripheral Blood and Disease Features Associated with Complement Components C3 and C4 in SLE


Session Type: ACR Meet the Professor
Sessions Session Time: 12:45 – 2:15 PM

# 014 – Pediatric Systemic Lupus Erythematosus. West – 3009
# 018 – Systemic Lupus Erythematosus: Lupus Nephritis. West – 3020


Session Type: Study Groups
Session Time: 01:00 – 2:00 PM
Session Location: West 2018

Session Title: Systemic Lupus Erythematosus: new data from Latin American patients

Coordinator: María L. Massardo MD (Chile).
Speakers: Luis A. González, MD (Colombia): Hematologic abnormalities and their impact in patients with SLE. Manuel F. Ugarte-Gil, MD (Peru): Flares in SLE: predictors and consequences. Guillermo J. Pons-Estel, MD, PhD (Argentina): Antimalarials in SLE. Main or supporting actor? Emila Sato, MD (Brazil): Conclusions and future perspectives for research in Latin America.


Session Type: ACR Concurrent Abstract
Sessions Session Time: 2:30 – 4:00 PM

Session Title: Health Services Research I: Digital Health and Patient, Provider Factors in Rheumatic Disease. North – 132

# 919. Automated Case Identification of Lupus from an Electronic Health Record Using Novel Informatics Approaches

# 920. Patient Preferences for the Development of a Mobile Health (mHealth) Application (App) for Systemic Lupus Erythematosus (SLE) Patients: A Qualitative Study

# 921. Poverty Associated with Increase in Damage in SLE over Two-Year Period

Session Title: Innate Immunity and Rheumatic Disease. West 2018

# 932. IRF4-Dependent and IRF4-Independent Pathways Contribute to DC Dysfunction in Lupus

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Epidemiology and Prognosis. South – Esplanade, 304

# 985. Improved Survival in Systemic Lupus Erythematosus: A Population-Based Study

# 986. Application of New EULAR Definitions of Remission in SLE: Durable 1-Year Remission Is Rare

# 987. Pre-Emptive Renal Transplantation Among End Stage Renal Disease Patients with and without SLE

# 988. Factors Associated with Renal Remission, Relapse and Long-Term Renal Function Decline in Lupus Nephritis Treated with Combined Prednisolone and Mycophenolate Mofetil (MMF) or Tacrolimus (Tac)

# 989. Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis

# 990. Performance of the Systemic Lupus International Collaborating Clinic Classification Criteria Versus the 1982 and Revised 1997 American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus: A Population-Based Study

Session Title: T cell Biology and Targets in Autoimmune Disease I - West – 2016

# 992. Therapeutic Targeting of CD4+ T Cell Metabolism in Murine Models of Lupus


Session Type: ACR Concurrent Abstract
Sessions Session Time: 4:30 – 6:00 PM

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Patient-Reported Measures, Outcomes and Reporting. South – Esplanade, 303

# 1063. Admissions and Readmissions of Patients with Systemic Lupus Erythematosus Is a Major Cause of Direct and Indirect Health Care Costs

# 1064. Feasibility and Validity of Patient Reported Outcome Measurement Information System (PROMIS) in SLE

# 1065. Atherosclerotic Vascular Events in a Multinational SLE Inception Cohort: Description and Predictive Risk Factors over a 15 Year Period

# 1066. Temporal Trends and Outcomes of Acute Myocardial Infarction in Systemic Lupus Erythematosus Hospitalizations

# 1067. Sex Differences in Rates of End-Stage Renal Disease and Death Among Medicaid Patients with Incident Lupus Nephritis

# 1068. Assessment of 10-Year Risk of Myocardial Infarction or Stroke in SLE

Session Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Genetics, Gene Expression, and Epigenetics. North – 130.

# 1069. Child’s HLA-DRB1 Genotype Increases Maternal Risk of Systemic Lupus Erythematosus: Results from the Mother-Child Immunogenetic Study in Autoimmunity

# 1070. CD 14(C-159T) Polymorphism and Soluble CD14 Are Associated with Increased Disease Activity and Nephritis in SLE

# 1071. Single-Cell RNA Sequencing of Human Podocytes, Endothelial Cells, and Tubular Cells Identifies Markers and Gene Profiles Differentiating Class IV and Class V Renal Disease in Lupus Nephritis

# 1072. Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE

# 1073. B Cell Subsets Are Epigenetically and Transcriptionally Dysregulated in Systemic Lupus Erythematosus

# 1074. DNA Methylation Patterns in Naïve CD4+ T Cells Identify Epigenetic Susceptibility Loci for Malar Rash and Discoid Rash in Systemic Lupus Erythematosus


Session Type: ACR Meet the Professor
Sessions Session Time: 4:30 – 6:00 PM

# 030 – Systemic Lupus Erythematosus: Novel Treatments - West – 3024


Session Type: ARHP
Sessions Session Time: 4:30 – 6:00 PM

Pediatric Lupus Transitional Care: An Interactive Experience. West – 2009



Monday, November 9, 2015
Session Type: ARHP
Sessions Session Time: 7:30 – 8:30 AM

New Therapeutics On the Horizon - West - 2004
New Therapeutic Approaches for SLE and Systemic Sclerosis. Speaker: Jennifer M. Grossman, MD


Session Type: ACR Meet the Professor
Sessions Session Time: 7:45 – 9:15 AM

*040 – Systemic Lupus Erythematosus: Novel Treatments – How to Treat Systemic Lupus Erythematosus – Speakers: Richard Furie MD and Liz Lighstone PhD. West - 3024


Session Type: ACR/ARHP Poster
Session B and Poster Tours Session Time: 9:00 – 11:00 AM

Guided Poster Tours 9:00 – 9:45 AM
# 318 - Systemic Lupus Erythematosus: Human Etiology.

Poster Tour 10:15 – 11:00 AM
# 322 - Systemic Lupus Erythematosus: Animal Models. Poster Tour
# 323 - Systemic Lupus Erythematosus: Clinical Aspects. Poster Tour

Session Title: B cell Biology and Targets in SLE, pSS, and other Autoimmune Disease

# 1111. Relapse of Lupus after B-Cell Depletion Therapy Is Associated with Loss of Apoptotic Cell Clearance and Elevated Type I Interferon Responses in Lupus Prone BXD2.

# 1112. Obinutuzumab Outperforms Rituximab at Inducing B-Cell Cytotoxicity in Vitro through Fc-Mediated Effector Mechanisms in Rheumatoid Arthritis and Systemic Lupus Erythematosus

# 1113. B Cell Signature Profiling in Systemic Lupus Erythematosus Patients on Belimumab

# 1114. Profiling Circulating Plasmablasts from Anti-Ro Positive Mothers of Children with Congenital Heart Block to Identify Antigenic Targets Conferring Pathogenicity

# 1115. B Cell-Intrinsic Interferon Gamma Signals Promote the Development of Systemic Lupus Erythematosus By Enhancing the Formation of Spontaneous Autoimmune Germinal Centers

# 1116. Decreased Expression of Negative Regulators of Toll-like Receptor Signaling and Increased TLR7 Responsiveness in Expanded IgD- CD27- B Cells from Systemic Lupus Erythematosus Patients

# 1117. The B Cell Survival Cytokine BAFF Promotes Systemic Lupus Erythematosus Via Activation of TACI, Not BAFF Receptor

# 1118. Role of the Chemokine Receptor CXCR3 in the Function of Regulatory B Cells in Patients with SLE

# 1119. High Resolution Motif Mapping of ‘in Situ’ Anti-Native-Vimentin Antibodies in Lupus Tubulointerstitial Nephritis

# 1120. Analysis of SLE Plasmablasts By High Throughput Pairing of the Immunoglobulin Heavy and Light Chain (VH-VL)

Session Title: Education Poster I (ARHP): Education/Community Programs

# 1199. The Charla De Lupus (Lupus Chat)® Program: An Evaluation of a Lupus Support Program for Teens, Young Adults and Parents

Session Title: Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

# 1235. Epidemiology of Kikuchi-Fujimoto Disease in Martinique and Characteristics in an Afro-Caribbean Population: Close Relation with Lupus

# 1236. Google-Driven Search for Autoimmune Big Data Links Air Pollution and Younger Age at Diagnosis of Systemic Lupus Erythematosus: Geoepidemiological Analysis of 171,000 Adult Patients

# 1237. The Incidence and Prevalence of Systemic Lupus Erythematous in a Defined Population in United Arab Emirates

# 1238 Incident Systemic Lupus Erythematosus in Males in a Northern California County Hospital

Session Title: Genetics, Genomics and Proteomics Poster II

# 1245. Differential DNA Methylation Associated with Lupus Nephritis Shows Enrichment in Genes Involved in Regulation of TH2 Differentiation and Renal Development

# 1249. Differential Expression of SLE Susceptibility Genes By Interferon-Alpha and the HLA-DRB1*03:01 Haplotype in Ex Vivo B Cells

# 1264. Residential Proximity to Highways, DNA Methylation and Systemic Lupus Erythematosus

Session Title: Health Services Research Poster II (ACR): Healthcare Access, Patterns of Medication Use and Workforce Considerations

# 1286. Persistent Individual and Neighborhood Poverty Are Independent Risk Factors for Accumulated Lupus Damage

# 1289. Healthcare Utilization Differences According to Sex Among Children and Adults in Medicaid with Incident Lupus Nephritis

Session Title: Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

# 1687. Increased Carotid Intima-Media Thickness in Psoriatic Arthritis Patients Compared with Systemic Lupus Erythematosus Patients and Healthy Controls

Session Title: Systemic Lupus Erythematosus - Animal Models Poster I

# 1750. Identification of Autoantibody-Inducing CD4 T Cell (aiCD4 T cell) That Causes Systemic Lupus Erythematosus (SLE) As DOCK8+ CD4 T Cell: Proof of Concept of Self-Organized Criticality Theory

# 1751. Modulation of IRF4 Function Promotes Expansion of Effector Tregs in Lupus

# 1752. Characterization of Epitopes Identified with Cerebral Vasculature Injury

# 1753. Response Gene to Complement-32 Promotes Plasma Cell Differentiation and Enhances Lupus-like Chronic Graft Versus Host Disease

# 1754. BANK1 Controls the Development of SLE By Modulating TLR7 Signaling and Type I IFN-Induced Translation Initiation Pathway in B Cells

# 1755. The Lymphotoxin/Megakaryoblastic Leukemia 1/Actin Axis As a Master Regulator of TLR Signaling in Lupus

# 1756. The Oxidative Burst Mediates Anti-Inflammatory Clearance of Dead Cells in a Mouse Model of SLE and Inflammatory Arthritis

# 1757. Absence of Estrogen Receptor Alpha Is Protective Against Nephrotoxic Serum-Induced Nephritis

# 1758. Alterations in Nuclear Structure Promote Lupus Autoimmunity in a Mouse Model

# 1759. Activation of T-Follicular Helper Cells and B Cells in Ultraviolet Light-Induced Murine Model of Systemic Lupus Erythematosus

# 1760. PD-1 Signaling Interferes with OX40 to Alter the Suppressive Function and Proliferation of CD4+ Regulatory T Cells in Lupus Mice

# 1763. Neutrophil Netosis Formation during the UVB Induced-Skin Inflammation

# 1764. Type 1 Interferon in the Skin Stimulated By Ultraviolet B Light Generates Immune Suppression Mediated By Idoleamine 2,3-Dioxygenase 1

# 1765. MiR155 Deficient Mice Show Reduced Disease Severity in Pristane-Induced Lupus

# 1766. HPV Vaccination of Nzbxw/F1 Mice

# 1767. Noninvasive Assessment of Macrophage Activation in Experimental Glomerulonephritis Using Optical Imaging with Near-Infrared Light Serves As a Surrogate of Disease Activity

# 1768. Improved Tissue Clearing and 2-Photon Imaging of Mouse Kidneys Reveals Immune Cell Architecture in Nephrotoxic Nephritis

Session Title: Systemic Lupus Erythematosus - Animal Models Poster II

# 1769. Role of Topical Administration of Peptidylarginine Deiminase Inhibitors in Murine Lupus

# 1770. A New Perspective in Extracorporeal Immunotherapy of Systemic Lupus Erythematosus: Dnase I-Based Blood Perfusion Experiment Using Rat Model

# 1771. Blockade of Immune Complex-Mediated Glomerulonephritis By Highly Selective Inhibition of Bruton’s Tyrosine Kinase

# 1772. Anti-Pentraxin 3 Antibodies Ameliorate Disease Manifestations and Lupus-like Nephritis in New Zealand Black/New Zealand White F1 Mice

# 1773. Pan JAK Inhibitor Tofacitinib Ameliorate Autoimmunity and Nephritis in Lupus Prone Mice Via Inhibition of Interferon Signaling Pathway

# 1774. Bone Marrow Derived Dendritic Cells Modified By Lentiviral-Mediated RelB shRNA Possess Tolerogenic Phenotype and Functions on Lupus Splenic Lymphocytes

# 1775. Fn14 Deficiency Protects Lupus-Prone Mice from Cutaneous Lesions Induced By Ultraviolet B (UVB) Irradiation

# 1777. Lymphocyte Depletion, Recovery and Efficacy in NZBWF1 Lupus Mice Following Continuous or Intermittent Dosing Regimen of Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor

# 1778. Disease Progression Is Altered By Moderate Exercise and Social Stress in a Murine Model of Lupus Nephritis

# 1779. Characterization of Anti-Nuclear Antibody (ANA) Signatures in Murine Models of Lupus Using Genalyte Maverick Technology

# 1780. Oxidative Stress Protects Against Nephritis Induced By Chronic Graft Versus Host Disease

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

# 1781. Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

# 1782. A Double-Blind, Randomized, Parallel-Group Study of Hydroxychloroquine on Cutaneous Lupus Erythematosus in Japan

# 1783. Dietary Fish Oil Supplementation Raises Serum Essential Fatty Acid Concentrations in Patients with Systemic Lupus Erythematosus and Correlates with Improvements in Inflammation and Pain

# 1784. Treatment with Belimumab in SLE Does Not Impair Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine

# 1785. Clinical Characteristics and Relative Factors of Infections in Southern Chinese Patients with Systemic Lupus Erythematosus

# 1786. Improvements in Health-Related Quality of Life and Fatigue Following Administration of an IL-6 Monoclonal Antibody (PF-04236921) in an Enriched Population of Subjects with Active SLE

# 1787. Innate Immunity, Arterial Inflammation and Vascular Stiffness in Patients with Systemic Lupus Erythematosus

# 1788. Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus

# 1789. Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register

# 1790. Mycophenolate Mofetil Suppresses Humoral Response to Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases

# 1791. Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients from Atherosclerotic Cardiovascular Events? a Case-Control Study

# 1792. Optimal Monitoring for Coronary Heart Disease Risk in Systemic Lupus Erythematosus Patients: a Systematic Review

# 1793 Is There a Relationship Between Antimalarial Treatment and Elevated Muscle Enzymes in Systemic Lupus Erythematosus

# 1794 Unexplained Decline in Rates of Cardiovascular Events in a Large Cohort of SLE Patients

# 1795 Long-Term Safety and Efficacy of Tacrolimus for Lupus Nephritis Patients in Real World Setting -Results from 5 Year Interim Analysis of Post Marketing Surveillance of 1376 Patients in Japan-

# 1797. Insulin Resistance Is Not Associated with Increased Risk of Subclinical Atheromatosis in Patients with Systemic Lupus Erythematosus from Northern Spain

# 1798. Progression of Noncalcified and Calcified Coronary Plaque (by CT Angiography) in SLE

# 1799. IgG Levels Correlate Inversely with Proteinuria Among Participants in the Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Trial, but Hypogammaglobulinemia Was Not Associated with an Increased Risk of Serious Infection

# 1800. A Novel Anti-CD28 Domain Antibody Antagonist Shows a Favorable Pharmacokinetic, Pharmacodynamic and Safety Profile

# 1801. Hydroxychloroquine Retinopathy: Application of the 2011 Screening Guidelines in an Academic Practice

# 1802. Hydroxychloroquine Level Variants and Predictors in a Connective Tissue Disease Population

# 1803. Serum Adipocyte Fatty Acid-Binding Protein Level Is Elevated in Patients with Systemic Lupus Erythematosus (SLE) but Not Associated with Biophysical Markers of Cardiovascular Disease

# 1804. Association of the Metabolic Syndrome (MetS) with Vascular Complications, End Stage Renal Failure (ESRF) and Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Cohort Analysis

# 1805. Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

# 1806. Hydroxychloroquine Serum Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis

# 1807. Estimated Sodium and Potassium Intake Are Associated with Blood Pressure in Patients with Systemic Lupus Erythematosus

# 1809. Real Life Implementation of Lupus Nephritis Randomized Controlled Trials

# 1810. A Five-Year Follow-up of Microvascular Dysfunction and Coronary Artery Disease in SLE: Results from a Community-Based Lupus Cohort

# 1811. Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus

# 1812. The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus

# 1813. Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production

# 1814. Efficacy of Isoniazid Chemoprophylaxis in Lupus Nephritis Patients

# 1815. Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence

# 1816. Long-Term Outcome of Tacrolimus Therapy As a Maintenance Strategy in Patients with Lupus Nephritis

# 1817. Myocardial Tissue Characterization with Native Myocardial T1 Mapping in SLE Patients with Chest Pain

# 1818. Cyclophosphamide and Cumulative Steroid Dose Associated with Higher Risk of Infections in Patients with Lupus Nephritis

# 1819. Comparison of Electrocardiographic ST-T Changes and QTc Duration in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

# 1820. Prevalence and Risk-Factors for Asymptomatic Coronary-Artery Calcifications in Young Patients with Systemic Lupus Erythematosus

# 1821. Leptin, Adiponectin, and Resistin As Serum Markers of Fatigue in Systemic Lupus Erythematosus: A Pilot Study

# 1822. Pharmacokinetics of the Selective B-Cell Lymphoma-2 (Bcl-2) Inhibitor, ABT-199, in Female Subjects with Systemic Lupus Erythromatosus

# 1823. Visceral Adiposity in Premenopausal Lupus Patients: Correlation with Systemic Inflammation

# 1824 Tripterygium Wilfordii for the Treatment of Systemic Lupus Systematosus: Meta-Analysis of Randomized Controlled Trials

# 1825. Osteoprotegerin Is Associated with Lupus and with Coronary Artery Calcification

# 1826. Small LDL-P Increases with Increased Disease Activity in SLE

# 1827. Plasma Myeloperoxidase Levels Are Inversely Associated with Carotid Plaque in SLE

# 1828. Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus

# 1829. Heart Rate Variability Is Associated with SLE Flare and with TNF- and IFN-Mediated Signaling

# 1830. Periodontal Disease in Lupus Erythematosus and Cardiovascular Risk Factors

# 1831. Initial Risk Factor Profile and Long-Term Cardiovascular Outcome in Women with Systemic Lupus Erythematosus

# 1832. Recurrence-Rate of Thrombotic Events in SLE Patients Negative for Antiphospholipid Antibodies

# 1833. Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and Osteoporosis

# 1834. Total Hip Arthroplasty Outcomes: A 17 Year Experience in a Single-Center: Is Systemic Lupus Erythematosus a Real Risk Factor for Adverse Outcomes?

# 1835. Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee Replacement

# 1836. Standardized Incidence Ratio (SIR), Time Trend and Risk Factors of Avascular Bone Necrosis (AVN) in Patients with Systemic Lupus Erythematosus (SLE)

# 1837. Predictability of Musculoskeletal Flares and Hand Deformities in Systemic Lupus Erythematosus By High Resolution Ultrasound : 5-Year Clinical and Imaging Prospective Follow-up Study

# 1838. Joint Ultrasonography May be Useful to Assess Disease Activity in Systemic Lupus Erythematosus (SLE) Patients: A Prospective Multicenter Study

# 1839. Safety and Immunogenicity of Quadrivalent Human Papilloma Virus (qHPV) Vaccine (Gardasil®) in Systemic Lupus Erythematous (SLE), Phase I Trial Completion

# 1840. How Good a Job Are We Rheumatologists Doing in Screening for Hepatitis B and C before Immuno-Suppressive/s Initiation in SLE?

# 1841. Meningitis in Systemic Lupus Erythematosus Patients: Epidemiologic Profile of Listeria Monocytogenes Infection. a Single-Center Study

# 1842. Systemic Lupus Erythematosus and Chikungunya Fever: Interactions during the 2014 Outbreak in Martinique

# 1843. Bloodstream Infections in Systemic Lupus Erythematosus Patients Are Associated with Severe Lupus Flares

# 1844. Risk Factors for Complicated Pneumonia in Systemic Lupus Erythematosus (SLE)

Session Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II

# 1845. HMGB1 Early Marker in Lupus Nephritis

# 1846. IGFBP-2 As a Novel Biomarker for Disease Activity and Renal Pathology in Lupus Nephritis

# 1847. Serum Ferritin and Insulin-like Growth Factor-Binding Protein 2 As Biomarkers of Clinical and Histopathological Treatment Response in Lupus Nephritis

# 1848. Increased Expression of Bruton Tyrosine Kinase in Patients with Lupus Nephritis and Its Clinic Significance

# 1849. Serum Axl and Tumor Necrosis Factor Receptor II Portend Long-Term Renal Outcome in Lupus Nephritis

# 1850. Increased Levels of Immunoglobulin Binding Protein 1 Are Associated with Disease Activity Including Renal Damage in Patients with Systemic Lupus Erythematosus

# 1851. Antibody Against Ribonuclease-H Is a Novel Autoantibody Specifically Recognized in Systemic Lupus Erhythematosus

# 1852. Association of Antibodies to the NR1 Subunit of N-Methyl-D-Aspartate Receptors with Neuropsychiatric Systemic Lupus Erythematosus

# 1853. Binding of a Novel IgG3 VH4-34 Monoclonal Antibody to ssRNA in SLE

# 1854. Identification and Characterization of microRNAs Related to the Pathogenesis of Cardiovascular Disease in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Role of Specific Autoantibodies

# 1855. Systemic Lupus Erythematosus Exosomes Contain Distinct RNA Transcripts That Differentiate Disease Activity and Modulate Cellular Function

# 1856. Exosomes from Patients with Active Systemic Lupus Erythematosus Induce a Strong Inflammatory Response

# 1857. Identification of the Long Noncoding RNA NEAT1 As a Novel Inflammatory Regulator Acting through MAPK Pathway in Human Lupus

# 1858. Serum Tartrate Resistant Acid Phosphatase (TRAP) Levels Are Decreased and Associated with Anti-Maa Antibodies in Systemic Lupus Erythematosus (SLE) Patients

# 1859. Anti-Interferon Autoantibodies in Systemic Lupus Erythematosus Are Biologically Active and Have Distinct Functions

# 1860. Autoantibodies Utilizing the Immunoglobulin Heavy Chain Variable Region Gene 4-34 (VH4-34) Exhibit Autoreactivity Towards, and Potential Competition with Galectins within Systemic Lupus Erythematosus (SLE)

# 1861. Anti-Ds-DNA Antibodies Regulate Atherothrombosis in Systemic Lupus Erythematosus through the Induction of Netosis and the Prothrombotic and Proinflammatory Activities of Monocytes

# 1862. Identification of Homogeneous Systemic Lupus Erythematosus (SLE) Patient Groups Using Clustered Autoantibody Reactivities

# 1863. Epigenetic Changes in SLE Implicate Enhancers As a Force in Pathologic Cell Behavior

# 1864. H3K4me3 Peak Shape Dictates Transcription and Regulates Differential Expression in SLE

# 1865. Association Between Changes in Expression of Gene Signatures and Disease Activity Among Patients with Systemic Lupus Erythematosus

# 1866. Fall in Dicer1 Gene Expression Flags Abnormal Lymphocyte Activation in Lupus

# 1867. Functional Androgen Receptor Variants Associated with Greater Damage in Systemic Lupus Erythematosus

# 1868. BLK Pathway-Associated rs13277113 GA Genotype Is More Frequent in Systemic Lupus Erythematosus Patients and Associated with Low Gene Expression and Increased Flares

# 1869. Association of CLEC16A with SLE in a Large Multi-Ancestry Cohort and Implication in B-Cell Receptor Signaling

# 1870. A Lupus-Associated Variant in Purine Nucleoside Phosphorylase (PNP) Causes Cell Cycle Abnormalities

# 1871. Familial Aggregation of Rheumatoid Arthritis, Sjögren’s Syndrome, and Systemic Sclerosis Were Detected in Systemic Lupus Erythematous Families

Session Title: T cell Biology and Targets in Autoimmune Disease Poster I

# 1934. Autophagy Pathway As a Target of Therapeutic P140 Peptide Used in Lupus

# 1935. Regulation of T Follicular Helper Cells in Systemic Lupus Erythematosus By E3 Ubiquitin Ligase Cbl-b


Session Type: ACR/ARHP Workshops
Session Time: 10:30 – 12:30 AM

# 221 – Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis. West – 3004


Session Type: ACR Plenary
Session Session Time: 11:00 – 12:30 AM
Session Location: South – Hall A

Session Title: ACR Plenary Session II: Discovery 2015

# 1994. Electronic Patient Reported Outcome Measures in Systemic Lupus Erythematosus: A Potential Disease Modifying Impact on the Management of Disease Activity Flares and Damage Accrual

# 1996. Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies.

Session Type: ACR Meet the Professor
Sessions Session Time: 12:45 – 2:15 PM

# 047 – Systemic Lupus Erythematosus: Central Nervous System. West – 3018
# 048 – Systemic Lupus Erythematosus: Lupus Nephritis. West – 3020


Session Type: Study Groups
Session Time: 1:00 – 2:00 PM
Session Location: West – 3014

Session Title: Medication Adherence and Decision-Making in Lupus Study Group
Speakers: Liana Fraenkel, MD, MPH; Jinoos Yazdany, MD, MPH and Lars Osterberg, MD, MPH


Session Type: ACR Concurrent Abstract
Sessions Session Time: 2:30 – 4:00 PM

Session Location: South – Esplanade 302
Session Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II


# 2016. Functional Tertiary Lymphoid Structures within the Kidneys of Lupus Prone Mice Resembles Lymph Nodes in Gene Expression Profiling Analysis and Are Detected By in Vivo Imaging

Session Location: South – Gateway Ballroom, 102
Session Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects II: Pediatric Systemic Lupus Erythematosus PEMd

# 2042. Pancreatitis Subtypes Survey in 852 Childhood-Onset Systemic Lupus Erythematosus Patients: A Multicenter Cohort

# 2043. Cell-Bound Complement Activation Products Have High Sensitivity and Specificity in Childhood-Onset Systemic Lupus Erythematosus and Juvenile Idiopathic Arthritis

# 2044. Axonal Dysfunction in Childhood-Onset Systemic Lupus Erythematosus. Association with Neuropsychiatric Manifestations and Disease Activity

# 2045. Cross-Validation of the Pediatric Automated Neuropsychological Assessment Metrics-Cognitive Performance Scores in the Screening of Neurocognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus

# 2046. Long-Term Outcomes in Cardiac Neonatal Lupus and Associated Risk Factors for Morbidity

# 2047. A Randomised Double-Blind Placebo-Controlled Trial of Vitamin D Supplementation in Juvenile-Onset Systemic Lupus Erythematosus: Effects on Microarchitecture Measured By HR-pQCT.

Session Location: West – 2001
Session Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Biomarkers

# 2066. Elevated Innate, Adaptive, and TNFSuperfamily Soluble Inflammatory Mediators Mark Impending Disease Flare, While Regulatory Mediators Distinguish Lack of Impending Disease Flare in African-American SLE Patients with Active Disease

# 2067. De-Convolution of Whole Blood Transcriptomic Data from a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept in Systemic Lupus Erythematosus

# 2068. Low Complement Is Associated with SLE Classification Criteria and Organ Damage

# 2069. High Interferon Gene Signature Is Associated with Increased Disease Activity, Reduced Complement C3 and C4, and Increased Oral Corticosteroid Use in Systemic Lupus Erythematosus (SLE).

# 2070. Urinary Biomarker Based “a-RAIL” Study in Adults with Lupus Nephritis

# 2071. Urinary Osteoprotegerin As Biomarker of Lupus Nephritis Disease Activity: Cross Sectional and Longitudinal Study

Session Location: North – 130
Session Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis: Modulators of Disease


# 2072. Mitochondrial Reactive Oxygen Species Modulate Autoimmunity in Systemic Lupus Erythematosus

# 2073. Mitochondrial ROS Is a Novel Regulator of Sting-Mediated Type I IFN Production By Governing Extrusion of Oxidized Mitochondrial DNA upon Neutrophil Extracellular Trap Formation.

# 2074. Dominant Chilblain Lupus Due to an Activating Mutation of Sting - Suppression of Constitutive Type I Interferon Activation By JAK Inhibition

# 2075. A Unique Naturally-Occurring Regulatory T Cell Subset Associated with Disease Activity in Patients with Systemic Lupus Erythematosus

# 2076. Development of Lupus Nephritis: Preclinical Evaluation of Patients Who Subsequently Develop Systemic Lupus Erythematosus Demonstrate Elevation of Select Soluble Mediators Prior to and at Disease Classification in Patients with Nephritis

# 2077. Does Dysbiosis within the Intestinal Microbiome Contribute to SLE Pathogenesis?


Session Type: ARHP
Sessions Session Time: 2:30 – 4:00 PM

Session Location: West – 2009
Session Title: Integrating Support and Education Programs Into Your Practice: Five Innovative Models

The Premise and Promise of Model Support and Education Programs: An Overview

Rheumatoid Arthritis Support and Education Programs

LupusLine®, Charla de Lupus (lLupus Chat)® Programs: Using a Peer Health Model to Speaker: Foster Provider Patient Partnership in New Ways

LANtern® (Lupus Asian Network): Servicing the Asian American Community


Session Type: ARHP Concurrent Abstract
Sessions Session Time: 2:30 – 4:00 PM

Session Location: West – 2004
Session Title: ARHP II: Lupus

# 2078. Reserve Capacity: Explaining the Link Between Socioeconomic Status and Depression/Anxiety Among Patients with Systemic Lupus Erythematosus

# 2079. Effectiveness of Renoprotective Approaches in Lupus Nephritis: More Than Just Immunosuppression

# 2080. Teaching Fellows in Lupus: Rheumatology Fellows Are Successful Educators in Improving Lupus Recognition By Frontline Healthcare Providers

# 2081. The SLE Workshop: An Evaluation of a Long-Standing Hospital-Based Psychoeducational Program

# 2082. Evaluations of Social Support Are Associated with Well-Being Outcomes in Women with Systemic Lupus Erythematosus (SLE)

# 2083. Predictors of Health Perceptions Among Women with Lupus


Session Type: ACR Concurrent Abstract
Sessions Sessions Session Time: 4:30 – 6:00 PM

Session location: West – 2011
Session Title: Genetics, Genomics, and Proteomics

# 2101. HLA Associations in Mothers of Children with Cardiac Manifestations of Neonatal Lupus

Session Location: West – 2014
Session Title: Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects


# 2120. Alterations in Complement C3 and iC3b in SLE Pregnancies

# 2121. Placentas of Lupus Pregnancies Are Characterized By Marked Inflammatory Changes Despite Good Disease Control

# 2122. A Novel Severity Score Based on Cardiac Neonatal Lupus Manifestations Serves As a Predictor and Outcome Measure of Morbidity in Anti-Ro Exposed Fetuses

# 2123. Incidence and Prognosis of Neonatal and Late-Onset Dilated Cardiomyopathy Associated with Cardiac Neonatal Lupus

# 2124. Racial Disparities in Lupus Pregnancy

# 2125. Rheumatic and Non-Rheumatic Autoimmune Diseases in SLE Offspring


Session Type: ACR Meet the Professor
Sessions Session Time: 4:30 – 6:00 PM

Session Title: # 057 – Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus – West – 3018


Session Type: ARHP Concurrent Abstract
Sessions Session Time: 4:30 – 6:00 PM

Session Location: West – 2016
Session Title: ARHP III: Epidemiology and Public Health


# 2173. Impact of Smoking on Patient-Reported Disease Status and Symptoms Among Women with Lupus



Tuesday, November 10, 2015
Session Type: ACR Meet the Professor
Sessions Session Time: 7:45 – 9:15 AM

# 070 – Systemic Lupus Erythematosus: Central Nervous System - West 3024.


Session Type: ACR/ARHP Workshops
Session Time: 7:45 – 9:15 AM

# 231 – Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis. West – 3004


Session Type: ACR
Sessions Session Time: 8:30 – 10:00 AM
Session Location: South – Hall A

Current Challenges in the Treatment of Systemic Lupus Erythematosus: Hope for the Future.


Session Type: ACR/ARHP Poster Session C and Poster Tours
Session Time: 9:00 – 11:00 AM

Guided Poster Tours 9:00 – 9:45 AM
# 329 - Systemic Lupus Erythematosus: Clinical Aspects Poster Tour

Session » Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

# 2897. Predictors of Organ Damage Progression and Impact on Health-Related Quality of Life in Systemic Lupus Erythematosus

# 2898. Erythrocytes, Acanthocytes, and Proteins in Urine Reflect Lupus Nephritis Histology

# 2899. Mortality Related to Pediatric Systemic Lupus Erythematosus: A Multiple Cause-of-Death Analysis in France

# 2900. Phospholipase A2 Receptor 1 Antibody in Membranous Lupus Nephritis

# 2901. Anti-dsDNA Antibodies Measured By Chemiluminescent Immunoassay Show Strong Association with Active Lupus Nephritis

# 2902. The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study

# 2903. Late-Onset Neutropenia Following Rituximab Treatment in Patients with Systemic Lupus Erythematosus

# 2904. Utility of Untimed Single Urine Protein/Creatinine Ratio As a Substitute for the 24 Hour Proteinuria for the Assessment of Proteinuria in Systemic Lupus Erythematosus

# 2905. Urinary Protein:Urinary Creatinine Ratio in an Untimed Urine Specimen and Estimated Glomerular Filtration Rate Are Reliable Measures of Proteinuria and Renal Function in Patients with Lupus Nephritis

# 2906. Can Immunosuppressive Drug Treatment Reduce Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Propensity Score Analysis of a Longitudinal Cohort of 803 Patients?

# 2907. The Natural History of Thrombotic Events in Systemic Lupus Erythematosus and Associated Risk Factors

# 2908. Diagnostic and Screening Accuracy of Spot Urinary Protein-Creatinine Ratio Compared to Protein Content in a 24 Hour-Urine Collection in Systemic Lupus Erythematosus: Systematic Review and Meta-Analysis

# 2909. A Systematic Review and Meta-Analysis of Cutaneous Manifestations in Late Versus Early-Onset Systemic Lupus Erythematosus

# 2910. How Accurate Is Spot Urine Protein/Creatinine Ratio in Measuring the Change over Time in Proteinuria Level Compared to the 24 Hour Proteinuria Test?

# 2911. Tubulointerstitial Involvement in Lupus Nephritis

# 2912. Concomitant Kidney Disease in Patients with Lupus Nephritis

# 2913. Intensified Treatment of B Lymphocyte Depletion (ITBLD) without Immunosuppressive Maintenance Treatment As a Rescue Therapy in Refractory Lupus Nephritis (LN): A 4-Year Observation

# 2914. Modifiable and Non-Modifiable Correlates of Satisfaction with Care in Systemic Lupus Erythematosus

# 2915. The Utility of Lupus Serology in Predicting Outcomes of Renal Transplantation in Lupus Patients: Systematic Review and Analysis of a Large Lupus Cohort

# 2916. Analysis of Risk Factors of the Progression to Chronic Kidney Disease and Comorbidities in Lupus Nephritis

# 2917. Combined Proliferative and Membranous Lupus Nephritis: Is the Prognosis Really Poor?

# 2918. Do Patients with Lupus Nephritis Who Achieve Complete Proteinuria Recovery at 2 Years Have Better Long Term Outcomes Compared to Patients with Partial Proteinuria Recovery?

# 2919. Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis

# 2920. Time to Recovery of Individual Lupus Manifestations on Standard of Care Treatment

# 2921. Lupus Nephritis: An Exploration of Management Style

# 2922. HLA-Specific Antibody Profile in Renal Transplant Patients with Systemic LUPUS Erythematosus

# 2923. The Effects of Disease Activity and Mood Disorders on Cognitive Function in Systemic Lupus Erythematosus

# 2924. Determinants of Damage in an SLE Cohort: Real World Data

# 2925. Factors Associated with Early Damage Accrual in Patients with Systemic Lupus Erythematosus: 12-Month Preliminary Results from the Inception Cohort of the Multicenter Early Lupus Project

# 2926. Cytochrome P450 Polymorphisms on Blood Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus

# 2927. Disease Activity Patterns over Time in Patients with SLE – a Retrospective Descriptive Analysis of the Hopkins Lupus Cohort

# 2928. Persistent Disease Activity over Time in a Large Canadian Cohort of Prevalent Lupus Patients

# 2929. Diet and Glucocorticoid Treatment in Patients with SLE

# 2930. Outcome of Patients with Systemic Lupus Erythematous (SLE) after Thrombotic Events

# 2931. Is Pregnancy a Risk Factor for the Onset of Systemic Lupus Erythematosus (SLE) in Women of the Reproductive Age: A Population Based Case-Control Study?

# 2932. A Retrospective Observational Study of Patients with Lupus Nephritis Treated with Rituximab in Combination with Cyclophosphamide

# 2933. Low Prevalence of PCP in Hospitalized Patients with SLE: Review of a Clinical Database Warehouse

# 2934. Endothelial Dysfunction in SLE-the Role of Platelets and Type I Interferon

# 2935. Disease Evolution in Late Onset and Early Onset Systemic Lupus Erythematosus (SLE)

# 2936. Evolution of Disease Burden over 7 Years in a Multicentre Inception SLE Cohort

# 2937. Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis

# 2938. Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort

# 2939. The Impact of Tabalumab on the Kidney in Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized Clinical Trials

# 2940. Risk Factors for Late-Onset Thrombosis in Systemic Lupus Erythematosus (SLE)

# 2941. Outcomes in Lupus Nephritis Patients Previously Randomized to Receive Either Low Dose Cyclophosphamide Versus Oral Mycophenolate Mofetil on Azathioprine Maintenance

# 2942. Longitudinal Analyses of Progression of Brain Athrophy in Childhood-Onset Systemic Lupus Erythematosus

# 2943. Preliminary Population-Based Incidence and Prevalence Estimates of Systemic Lupus Erythematous from the Manhattan Lupus Surveillance Program

# 2944. Presepsin (sCD14 subtype) Concentration Is Elevated and Reflects Disease Activity in Systemic Lupus Erythematous Patients

# 2945. Diffuse Alveolar Hemorrhage in SLE: Risk Factors, Response to Therapy, and Survival

# 2946. Mortality Among SLE Patients in the National Data Bank for Rheumatic Diseases

# 2947. Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus

# 2948. How Do Patients with Newly Diagnosed SLE Present? a Multicenter Cohort Analysis to Inform the Development of New Classification Criteria for SLE

# 2949. Differential Serum Cytokine Profile in Patients with Systemic Lupus Erythematosus and Posterior Reversible Encephalopathy Syndrome: A Single-Center Study

# 2950. Using Electronic Health Record Algorithms to Accurately Identify Patients with Systemic Lupus Erythematosus

# 2951. Anti-NR2 Antibody and Blood-Brain Barrier Disruption in Systemic Lupus Erythematosus Patients with Cognitive Dysfunction

# 2952. Diagnosis of Primary Neuropsychiatric Systemic Lupus Erythematosus: Attribution Models Versus Physician Judgment

# 2953. The Emergency Room and SLE: What Characteristics Are Associated with Increased Emergency Room Utilization in Lupus Patients?

# 2954. Serum and CSF Biomarkers of Neuropsychiatric Involvement in Primary Sjogren Syndrome and Systemic Lupus Erythematosus

# 2955. Cognitive Impairment in Lupus Patients: Identification of the Best Screening Test and Assessment for Associated Factors

# 2956. Patients’ Reported Perceived Deficits Questionnaire – 5-Item Is Not Valid to Screen for Cognitive Impairment in Lupus

# 2957. 25-Hydroxyvitamin D3 Deficiency Independently Predicts Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Results from a Controlled Study

# 2958. Vitamin D, Cognition and Cerebral Structural Abnormalities in Childhood- Onset Systemic Lupus Erythematosus

# 2959. Patterns of Vascular Brain Injury in Systemic Lupus Erythematosus Patients with Ischemic Stroke: Impact on Neuropsychological, Neurobehavioral and Physical Function Outcome


Session Type: ACR
Sessions Session Time: 11:00 – Noon

Systemic Lupus Erythematosus 2015: Arthritis, Bone Loss, Pregnancy and Nephritis
Speaker: Bevra H. Hahn, MD. South – Gateway Ballroom, 104


Session Type: ACR Meet the Professor
Sessions Session Time: 12:45 – 2:15 PM

*079 – Systemic Lupus Erythematosus: Novel Treatments – How to Treat Systemic Lupus Erythematosus. West – 3022
Speaker: Richard Furie, MD


Session Type: ACR Concurrent Abstract
Sessions Session Time: 2:30 – 4:00 pM

South – Esplanade, 307
2015 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship


# 3080. Histone H2AX Phosphorylation As a Measure of DNA Double Strand Breaks and a Marker of Environmental Stress and Disease Activity in Lupus

# 3081. IRF5 Deletion Prevents the SLE-like Disease Initiated By Dendritic Cell-Specific Loss of Caspase 8

# 3082. Nanogel Based Delivery of an Inhibitor of Calcium/ Calmodulin- Dependent Protein Kinase 4 Suppresses Experimental Autoimmune Encephalomyelitis and Lupuslike Disease in Mice

# 3083. Antibody Array Based Proteomic Screening of 274 Serum Markers in Systemic Lupus Erythematosus

# 3084. Progression of Lupus Pathology Is Correlative with Cardiac Magnetic Resonance Imaging Abnormalities, Diminished Function, and Inflammatory Histopathology in an Animal Model

# 3085. Platelet Activation and Endothelial Reactivity in the Pathogenesis of Tissue Inflammation/Injury in Systemic Lupus Erythematosus

West – 2000
Systemic Lupus Erythematosus – Clinical Aspects and Treatment V: Neuropsychiatric Lupus


# 3122. A Longitudinal Analysis of Change in Lupus Nephritis in an International Inception Cohort Using a Multistate Markov Model Approach

# 3123. Evidence of Altered Blood Brain Barrier Permeability in Systemic Lupus Erythematosus Using Magnetic Resonance Imaging

# 3124. Associations of Circulating Cell-Free Micro-RNA with Vasculopathy and Vascular Events in SLE Patients

# 3125. White Matter Magnetization Transfer Ratio Histogram Peak Height Helps Identifying Inflammatory Neuropsychiatric Systemic Lupus Erythematosus

# 3126. Biomarkers Associated with Hyperintense White Matter Lesions in Systemic Lupus Erythematosus

# 3127. Serologic Diagnosis of Human Neuropsychiatric Lupus Using the Immunarray ICHIP®


Session Type: ACR Concurrent Abstract
Sessions Session Time: 4:30 – 6:00 PM

West – 2014
B cell Biology and Targets in Autoimmune Disease: Novel B Cell Roles in Rheumatoid Arthritis and Systemic Lupus Erythematosus


# 3157. B Cell Profile As a Biomarker of Disease Segmentation and Flare Prognosis in SLE

West – 2000
Epidemiology and Public Health IV: Risk Factors and Comorbidities for Systemic Lupus Erythematosus and Psoriatic Arthritis

# 3158. Impact of Family History of Systemic Lupus Erythematosus on Risk of Autoimmune Diseases:

# 3159. Systemic Lupus Erythematosus Is a Risk Factor for Young Stroke: A Population-Based Cohort Study

# 3160. Comparative Rates of Serious Infections and All-Cause Mortality Among Systemic Lupus Erythematosus Patients Receiving Mycophenolate Mofetil Versus Azathioprine

# 3161. Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus

# 3162. Prevalence of Chronic Comorbidities in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Systemic Lupus Erythematosus: An Analysis of UK Biobank Data

# 3163. The Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients

West – 2016
Systemic Lupus Erythematosus – Animal Models


# 3212. Characterizing the Effects of the G-CSF-R Coding rs13377964 SNP Located within Murine Lupus Susceptibility Locus Sle2c2

# 3214. Impaired Phagocytosis of Apoptotic Cells in Pristane-Induced Lupus Simulates the Clearance Defect in Human SLE

# 3215. Bim Suppresses the Development of SLE By Limiting Macrophage Inflammatory Responses

# 3216. T Cell Restricted Deletion of Serine/Arginine- Rich Splicing Factor 1 (SRSF1) in Mice Causes Immune Cell Dysfunction and Contributes to Lupus-like Nephritis

# 3217. Macrophage Depletion Using a Specific CSF-1R Kinase Inhibitor Ameliorates Kidney and Skin Disease in a Mouse Model of Systemic Lupus Erythematosus

South – Esplanade, 304
Systemic Lupus Erythematosus – Clinical Aspects and Treatment VI: Novel Therapies


# 3218. A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)

# 3219. Efficacy and Safety of 4 Weeks Administration of Arsenic Trioxide in Moderate Active Systemic Lupus Erythematosus. a Phase I/II Proof-of-Concept Sequential Dose Escalation Multicenter Study

# 3220. Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial

# 3221. Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus

# 3222. Repeated Administration of Dapirolizumab Pegol (DZP) Appears Safe and Well Tolerated in Patients with Systemic Lupus Erythematosus (SLE) and Is Accompanied By an Improvement in Disease Activity: Results from a Phase 1 Study

# 3223. Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)


Session Type: ACR Meet the Professor
Sessions Session Time: 4:30 – 6:00 PM

# 087 – Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus
Speaker: Eliza Chakravarty, MD, MS - West – 3018



Wednesday, November 11, 2015
Session Type: ACR
Sessions Session Time: 9:00 – 10:30 AM
Session Location: South – Gateway Ballroom, 104

Racial Disparities in Rheumatic Diseases

Racial and Ethnic Disparities in Rheumatoid Arthritis. Jennifer Barton, MD

Impact of Race and Ethnicity on Outcomes in Systemic Lupus Erythematosus. Ernest Vina, MD, MS

Racial Disparities in Joint Arthroplasty. Susan M. Goodman, MD
inc_view_static_content.htm
File: inc_herra_s_related_gallery.htm
Location Map: Discover our Centers in Latin America
Suscribe to our Newsletter
Subscribe and receive all the news in your email.
Contact us
Questions or suggestions please contact Gladel.
inc_panel_right.htm

File: frontend_view_content.htm